|
| Press Releases |
|
 |
|
| Monday, March 24, 2025 |
|
|
エーザイ、女性活躍推進に優れた上場企業として令和 6 年度「なでしこ銘柄」に2 回目の選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、女性活躍推進に優れた上場企業として、経済産業省と東京証券取引所より、令和 6 年度「なでしこ銘柄」に選定されたことをお知らせします。2 年連続の選定となります。 more info >> |
|
| Monday, March 10, 2025 |
|
|
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time |
| Eisai Co., Ltd. announced today that it has been recognized as the 2025 KENKO Investment for Health by Japan's Ministry of Economy, Trade, and Industry (METI) and the Tokyo Stock Exchange, for the first time as a company strategically carrying out efforts with regard to its employees' health from a management perspective. more info >> |
|
|
エーザイ、「健康経営銘柄2025」に初選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、本日、当社が従業員の健康管理を経営的な視点から考え、戦略的に取り組んでいる企業として、経済産業省と東京証券取引所が共同で実施する「健康経営銘柄 2025」に初めて選定されたことをお知らせします。 more info >> |
|
| Wednesday, March 5, 2025 |
|
|
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan |
| Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025. more info >> |
|
| Tuesday, March 4, 2025 |
|
|
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia). more info >> |
|
|
佐藤製薬とエーザイ、経口抗真菌剤「ネイリン カプセル100mg」の日本におけるコ・プロモーションについて発表 |
| 佐藤製薬株式会社（本社：東京都港区、代表取締役社長：佐藤誠一、以下 佐藤製薬）、エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、佐藤製薬が製造販売する経口抗真菌剤「ネイリン®カプセル100mg」（一般名：ホスラブコナゾール、以下 本剤）に関する日本におけるコ・プロモーション契約に基づくコ・プロモーションを 2025 年 3 月 31 日をもって終了いたします。また、同時に佐藤製薬とエーザイは2025 年4月1日から2026年3月31日までを移行期間として、エーザイが本剤のプロモーション活動と佐藤製薬への業務の移管を行う新たな契約（以下 本契約）を締結したことをお知らせします。 more info >> |
|
| Monday, March 3, 2025 |
|
|
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" |
| Eisai Co., Ltd. announced today the launch of the new nutritional drink "Chocola BB Nightwell" (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3. more info >> |
|
|
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Abeta; monoclonal antibody lecanemab, adopted in November 2024. more info >> |
|
|
エーザイ、指定医薬部外品ドリンク「チョコラBBナイトウェル」新発売 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、生活者の皆様のキレイと元気を応援するチョコラBBブランドから、今日のたまった疲れを寝ている間に回復する栄養ドリンク「チョコラBBナイトウェル」（指定医薬部外品）を３月３日（月）に全国の薬局・薬店、ドラッグストアにて新発売します。 more info >> |
|
| Friday, February 28, 2025 |
|
|
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone |
| Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Indonesia at COP30: Leading Tangible Progress Toward NZE 2060, PLN at the Forefront of the National Energy Transition
Nov 15, 2025 21:00 HKT/SGT
|
|
|
寵物食品革命：兩項全球新調查揭示飼主對狗與貓永續飲食的接受度日益提升
Nov 15, 2025 12:00 HKT/SGT
|
|
|
Shoucheng Q3 Results: 30% Revenue Growth and HK$1B Buyback Plan Signal Confidence
Nov 15, 2025 10:05 HKT/SGT
|
|
|
三季报再度超预期：收入净利高增 回购升级10亿 首程控股加速迈向成长新阶段
Nov 15, 2025 10:05 HKT/SGT
|
|
|
三季報再度超預期：收入淨利高增 回購升級10億 首程控股加速邁向成長新階段
Nov 15, 2025 10:05 HKT/SGT
|
|
|
Pet-Food Revolution: Two New Global Surveys Reveal Growing Guardian Openness to Sustainable Diets for Dogs and Cats
Nov 14, 2025 22:00 HKT/SGT
|
|
|
Hitachi Employee Receives the "Chop Wood Carry Water Award" from the Global OSS Organization CNCF for Leading the Establishment of Official Community in Japan
Nov 14, 2025 21:06 JST
|
|
|
Eternal Group at Cosmoprof Asia 2025, The Fragrance Frontier: How Scent is Revolutionizing Spatial Design and the Olfactory Economy
Nov 14, 2025 17:32 HKT/SGT
|
|
|
穎通集團於亞太區美容展2025 揭示香氛跨界空間設計 嗅覺經濟新浪潮
Nov 14, 2025 17:32 HKT/SGT
|
|
|
颖通集团于亚太区美容展2025 揭示香氛跨界空间设计 嗅觉经济新浪潮
Nov 14, 2025 17:32 HKT/SGT
|
|
|
Chuangxin Industries Holdings Limited, a Green Electrolytic Aluminum and Alumina Producer, Announces its Plan to List on the Main Board of the Hong Kong Stock Exchange
Nov 14, 2025 14:14: JST
|
|
|
Chuangxin Industries Holdings Limited, a Green Electrolytic Aluminum and Alumina Producer, Announces its Plan to List on the Main Board of the Hong Kong Stock Exchange
Nov 14, 2025 13:14 HKT/SGT
|
|
|
綠色電解鋁及氧化鋁生產商 創新實業集團有限公司宣佈於香港聯合交易所主板上市計劃
Nov 14, 2025 13:14 HKT/SGT
|
|
|
アリックスパートナーズ、世界のEVバッテリー業界レポートを発表
Nov 14, 2025 11:00: JST
|
|
|
創新實業今起招股 入場費約5550港元
Nov 14, 2025 09:16 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
